Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Do ctDNA-based multicancer early detection (MCED) tests lead to overdiagnosis?
A new 5-year analysis from the case-control Circulating Cell-free Genome Atlas (CCGA) study explored the prognostic meaning of MCED results.
(CSD = cancer signal detected ; NCSD = no cancer signal detected)
Key findings:
- CSD: 5-yr OS 43% vs 40% in matched SEER population
- NCSD: 5-yr OS 88% vs 81% in SEER
Importantly, early-stage CSD cancers had survival similar to the matched SEER population, suggesting MCED is unlikely to simply detect indolent tumors (i.e., limited evidence of overdiagnosis).
But a critical clinical question remains:
If early-stage cancers are CSD-positive (ctDNA detected), should they be managed differently?”
Title: Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis
Auhtors: Charles Swanton, Alan Bryce, Allen L. Cohn, Matthew Margolis, Earl Hubbell, April Sagan, Oliver Venn, and Michael Seiden.
Other articles featuring Ahmet Dirican on OncoDaily.